Search results for: 'complex next'

23 Oct 2020  |  North America  |  Market Research

Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026

Outsourced Manufacturing of the Complex Third Wave of Biosimilars to Spark New Growth Opportunities

Infographics

×

Key Issues Addressed

In this research service, the Transformational Health team at Frost & Sullivan provides critical insights into the global biosimilar industry, highlighting the key growth opportunities, market revenue forecasts, and trends that will influence the industry with the emergence of the third wave of biosimilars. The global third-wave biosimilars market ...

13 Sep 2021  |  North America  |  Market Research

Global Small Molecule Contract Development and Manufacturing Organization (CDMO) Growth Opportunities

Emerging Pharmaceuticals and Highly Potent Complex Molecules Creating Future Growth Potential

Infographics

×

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global small molecule contract development and manufacturing organization (CDMO) industry. It highlights key growth opportunities for small molecule CDMOs based on the main evolution in their business models and strategic approaches as well as those of p...

24 Aug 2021  |  North America  |  Market Research

US and EU Biotech Industry VC Investment Growth Opportunities

Future Growth Potential Driven by Next-generation Cell and Gene Platform Technology Powered by AI

Infographics

×

With this research service, Frost & Sullivan provides critical insights into the biotech, and cell and gene therapy (CGT) venture capital (VC) investment trends highlighting the growth opportunities, key countries in the VC environment, and major trends in cell and gene therapy segment. The study also identifies actionable growth opportunities for ...

19 Aug 2022  |  North America  |  Market Research

Global Antibody Therapeutics Growth Opportunities

The Evolution of Next-generation Immuno-oncology Therapies for Multiple Tumor Antigens is Poised to Drive Market Growth

Infographics

×

Market growth is likely to be fueled by the growing utilization of cost-effective and efficient continuous manufacturing processes and single-use bioreactors for production, which will also reduce the time between development and commercialization. Favorable regulatory reforms in emerging Asian countries are encouraging the manufacture and introduc...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

An increasing focus on biologics, genomics, and multi-omics; the adoption of digital technologies; and a shift to patient-centric models are transforming the life sciences industry. At the same time, the emergence of value-based models, R&D activities to treat complex diseases, and healthcare consumerism provide an impetus to precision medicine. Wi...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...